Organization
Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences)
8 abstracts
Abstract
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.Org: Guangdong Lung Cancer Institute, Southern Medical University, First Affiliated Hospital of Zhengzhou University, Shanxi Cancer Hospital, The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University,
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
An MRI-based multi-parameter clinical decision support system (NeoMDSS) for early prediction of pathological complete response after the first cycle of neoadjuvant therapy in breast cancer: A multi-center prospective observational cohort study.Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Academy of Medical Sciences, Southern Medical University, Department of Vascular Surgery,
Abstract
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,
Abstract
BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in-human phase I study in patients with advanced solid malignancies.Org: Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Biocity Biopharmaceutics, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, West China Hospital of Sichuan University, Zhongshan Hospital of Fudan University, Shanghai, China, Huashan Hospital Fudan University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China,
Abstract
Magnetic resonance imaging tumor regression shrinkage patterns during neoadjuvant chemotherapy versus neoadjuvant immunochemotherapy in triple-negative breast cancer (NeoMDSS-TN-SP): A nonrandomized, prospective cohort study.Org: Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou JOYO Pharma,
Abstract
Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, Genesis Care North Shore, North Shore Health Hub, St Leonards, NSW, Australia,